Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.00.
Several equities analysts recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd.
Check Out Our Latest Analysis on ADPT
Hedge Funds Weigh In On Adaptive Biotechnologies
Adaptive Biotechnologies Price Performance
Shares of NASDAQ:ADPT opened at $4.70 on Wednesday. The company has a market cap of $692.63 million, a price-to-earnings ratio of -3.15 and a beta of 1.44. The firm has a 50 day simple moving average of $4.70 and a 200 day simple moving average of $3.94. Adaptive Biotechnologies has a one year low of $2.28 and a one year high of $5.80.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.02. The business had revenue of $43.19 million during the quarter, compared to the consensus estimate of $38.63 million. Adaptive Biotechnologies had a negative net margin of 126.49% and a negative return on equity of 60.99%. The firm’s revenue was down 11.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.33) EPS. As a group, analysts expect that Adaptive Biotechnologies will post -1.19 EPS for the current year.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- How to Invest in the Best Canadian StocksĀ
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Election Stocks: How Elections Affect the Stock Market
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Dividend Challengers?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.